Exploring personalized treatment for recurrent gynecological cancers
A Real-world Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on Molecular Profiling and Multidisciplinary Team Consultation
This study is testing if using genetic information to guide treatment can help improve outcomes for people with recurrent ovarian, cervical, or endometrial cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 2 sites (Guangzhou, Guangdong and 1 other locations) |
| Trial ID | NCT06781151 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effectiveness of genomic sequencing and molecular tumor boards in guiding personalized treatment for patients with recurrent ovarian, cervical, or endometrial cancer. It consists of two parts: a retrospective analysis of past patient data and a prospective enrollment of 200 patients. The study aims to assess whether targeted therapies based on molecular profiling can lead to improved clinical outcomes. Data will be collected from multidisciplinary consultations and treatment responses following genomic sequencing.
Who should consider this trial
Good fit: Ideal candidates include patients aged 18 and older with recurrent ovarian, cervical, or endometrial cancer who are referred for multidisciplinary consultation and have sufficient tumor tissue for genomic sequencing.
Not a fit: Patients with concurrent malignancies or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective personalized treatment options for patients with recurrent gynecological cancers.
How similar studies have performed: While the approach of using genomic sequencing and molecular tumor boards is gaining traction, this specific study's methodology is relatively novel and has not been extensively tested in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with recurrent ovarian, cervical, or endometrial cancer referred for multidisciplinary consultation by a gynecological oncologist; * Presence of at least one evaluable lesion; * Willingness to participate in multidisciplinary consultation; * Age 18 years or older; * Sufficient tumor tissue for next-generation sequencing (NGS) with a tumor content greater than 32%; * Informed consent provided by the participant, indicating understanding of the study procedures and willingness to participate. Exclusion Criteria: * Patients with concurrent malignancies; * Pregnant patients.
Where this trial is running
Guangzhou, Guangdong and 1 other locations
- Sun Yat'sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)
- Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center — Shenzhen, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Jihong Liu, PhD — Sun Yat'sen University Cancer Center
- Study coordinator: Xiaolin Luo, PhD
- Email: luoxl@sysucc.org.cn
- Phone: 15017599965
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.